Yann-Alexandre Vano, Georges-Pompidou European Hospital, Paris, France, discusses his best bits within the European Society for Medical Oncology (ESMO) Virtual Meeting 2020, highlighting genitourinary (GU) cancers including prostate, bladder and kidney cancer. Dr Vano highlights the CheckMate 9ER clinical trial (NCT03141177) and the NIVOREN trial (NCT03013335) for renal cell carcinoma. For urothelial carcinoma, his top picks include the COSMIC-021 trial (NCT03170960), TROPHY-U-01 trial (NCT03547973), KEYNOTE-361 trial (NCT02853305) as well as the DANUBE study (NCT02516241). Additionally, Dr Vano is looking forward to the updates on the PROfound study (NCT02987543) and the IPATential150 trial (NCT03072238) in patients with metastatic castration-resistant prostate cancer. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).